Dale R. Tavris,Beverly Gallauresi,Ralph G. Brindis
标识
DOI:10.1002/9780470060872.ch25
摘要
This chapter contains sections titled: The ideal vascular hemostasis device Origin of FDA concern with the postmarket performance of hemostasis devices FDA study to evaluate the risk associated with hemostasis device use Possible reasons for FDA findings of apparent protective effects of hemostasis devices Follow-up FDA study to assess the safety of hemostasis devices Conclusion References